• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Altimmune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/13/26 7:34:07 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALT alert in real time by email
    ALTIMMUNE, INC._May 13, 2026
    0001326190false00013261902026-05-132026-05-13

    ​

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 13, 2026

    ALTIMMUNE, INC.

    (Exact name of registrant as specified in its charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Delaware

     

    001-32587

     

    20-2726770

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    ​

    ​

    ​

    ​

    ​

    910 Clopper Road, Suite 201S

    Gaithersburg, Maryland

    ​

    ​

    ​

    20878

    (Address of principal executive offices)

    ​

    ​

    ​

    (Zip Code)

    ​

    Registrant’s telephone number including area code: (240) 654-1450

    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ​

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common stock, par value $0.0001 per share

    ALT

    The NASDAQ Global Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    ​

    Item 2.02 Results of Operations and Financial Condition

    On May 13, 2026, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its first quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing.

    ​

    Item 9.01 Financial Statements and Exhibits

    ​

    (d) Exhibits

    ​

    ​

    ​

    No.

      ​

    Description

    ​

    ​

    ​

    99.1

    ​

    Press Release of Altimmune, Inc. dated May 13, 2026

    ​

    ​

    ​

    104

    ​

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    ​

    ​

    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

    ​

    ALTIMMUNE, INC.

    ​

    ​

    ​

    ​

    ​

    By:

     

    /s/ Gregory Weaver

    ​

    ​

     

    Name: Gregory Weaver

    ​

    ​

     

    Title: Chief Financial Officer

    ​

    Dated: May 13, 2026

    ​

    Get the next $ALT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALT

    DatePrice TargetRatingAnalyst
    4/24/2026$2.50Sell → Neutral
    Goldman
    3/18/2026$12.00Buy
    Truist
    1/28/2026$20.00Overweight
    Barclays
    7/10/2025$1.00Sell
    Goldman
    2/28/2025Mkt Perform
    William Blair
    1/8/2025$18.00Buy
    Stifel
    11/12/2024$26.00Buy
    UBS
    4/29/2024Buy → Neutral
    Guggenheim
    More analyst ratings

    $ALT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lawver Teri L

    4 - Altimmune, Inc. (0001326190) (Issuer)

    5/1/26 4:23:16 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sohn Catherine A.

    4 - Altimmune, Inc. (0001326190) (Issuer)

    5/1/26 4:20:49 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Jorkasky Diane

    4 - Altimmune, Inc. (0001326190) (Issuer)

    5/1/26 4:18:40 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Durso Jerome Benedict bought $70,790 worth of shares (20,000 units at $3.54), increasing direct ownership by 160% to 32,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:00:05 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pisano Wayne bought $20,410 worth of shares (5,000 units at $4.08), increasing direct ownership by 59% to 13,498 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    1/9/26 4:10:05 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Altimmune Inc.

    SCHEDULE 13G/A - Altimmune, Inc. (0001326190) (Subject)

    5/15/26 4:15:13 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Altimmune Inc.

    S-8 - Altimmune, Inc. (0001326190) (Filer)

    5/13/26 4:17:43 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Altimmune Inc.

    10-Q - Altimmune, Inc. (0001326190) (Filer)

    5/13/26 4:13:42 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

    "Best of EASL" oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple cardiometabo

    5/28/26 11:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune to Participate in Upcoming Investor Conferences

    GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare ConferenceThursday, June 4, 2026Fireside chat at 12:50 p.m. ETNew York, NY Goldman Sachs 47th Annual Global Healthcare Conference Wednesday, June 10, 2026Fireside chat at 8:00 a.m. ETMiami Beach, FL A webcast of the fireside chats will be available via the Events section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical co

    5/27/26 8:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

    Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate antifibrotic effects of pemvidutide at 24 weeks GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new analyses of data from the IMPACT Phase 2b trial demonstrated that treatment with pemvidutide, an investigational, balanced 1:1 glucagon/GLP-1 dual receptor agonist, is associated with concurrent improvements across multiple non-invasive tes

    5/27/26 8:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Altimmune upgraded by Goldman with a new price target

    Goldman upgraded Altimmune from Sell to Neutral and set a new price target of $2.50

    4/24/26 7:59:47 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Altimmune with a new price target

    Truist initiated coverage of Altimmune with a rating of Buy and set a new price target of $12.00

    3/18/26 4:00:13 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Altimmune with a new price target

    Barclays initiated coverage of Altimmune with a rating of Overweight and set a new price target of $20.00

    1/28/26 7:15:18 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Leadership Updates

    Live Leadership Updates

    View All

    Altimmune Announces CEO Transition and Succession Plan

    Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company's President and Chief Executive Officer effective January 1, 2026. Altimmune's Chairman of the Board, Jerry Durso, will assume the role of President and Chief Executive Officer and retain his position as Chairman. To facilitat

    12/1/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

    GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine. During her career, she has led multiple product launches, built successful commercial franchises

    9/15/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Financials

    Live finance-specific insights

    View All

    Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

    GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on May 13 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the

    5/6/26 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

    GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on t

    2/26/26 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

    Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorable tolerability profile of pemvidutide preserved at 48 weeks, reinforced by low treatment-related discontinuation rate End-of-Phase 2 meeting with FDA supports advancing to registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis Conference call to be held today at 8:00 a.m. ET GAITHERSBURG, Md., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing thera

    12/19/25 6:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    11/14/24 11:58:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    10/17/24 11:16:51 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    10/16/24 4:21:16 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care